Prevention of Femoropopliteal In-Stent Restenosis with Cilostazol

Angiology

Volumn 67, Issue 6, 2016, Pages 549-555

  Iftikhar, Omer ^a   Oliveros, Karla ^b   Tafur, Alfonso J ^c   Casanegra, Ana I ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSIDAD CATÓLICA DE SANTIAGO DE GUAYAQUIL   (Ecuador)

^c NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

cilostazol; peripheral arterial disease; primary patency; stenosis; stent

Indexed keywords

CILOSTAZOL; CARDIOVASCULAR AGENT; TETRAZOLE DERIVATIVE;

ARTICLE; BIBLIOGRAPHIC DATABASE; CRITICAL LIMB ISCHEMIA; DISEASE SEVERITY; DRUG USE; FEMORAL ARTERY STENT; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; NITINOL STENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY CONTROL; SELF EXPANDING STENT; SUPERFICIAL FEMORAL ARTERY; DEVICES; DIAGNOSTIC IMAGING; DRUG EFFECT; ENDOVASCULAR SURGERY; FEMORAL ARTERY; META ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POPLITEAL ARTERY; PROTECTION; RECURRENT DISEASE; RISK FACTOR; STENT; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY;

CARDIOVASCULAR AGENTS; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; HUMANS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROTECTIVE FACTORS; RECURRENCE; RISK FACTORS; STENTS; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 84970952335     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715604768     Document Type: Article

References (43)

1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006; 113 (11): e463-e654.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG,. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45 (suppl S): S5-S67.
3. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382 (9901): 1329-1340.
4. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009; 120 (21): 2053-2061.
5. Heald CL, Fowkes FG, Murray GD, Price JF,. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis. 2006; 189 (1): 61-69.
6. McDermott MM, Applegate WB, Bonds DE, et al. Ankle brachial index values, leg symptoms, and functional performance among community-dwelling older men and women in the lifestyle interventions and independence for elders study. J Am Heart Assoc. 2013; 2 (6): e000257.
7. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM,. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009; 50 (1): 54-60.
8. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006; 354 (18): 1879-1888.
9. Earnshaw JJ, Whitman B, Foy C,. National Audit of Thrombolysis for Acute Leg Ischemia (NATALI): clinical factors associated with early outcome. J Vasc Surg. 2004; 39 (5): 1018-1025.
10. Kimura Y, Tani T, Kanbe T, Watanabe K,. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 1985; 35 (7A): 1144-1149.
11. Kohda N, Tani T, Nakayama S, et al. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999; 96 (4): 261-268.
12. Ishizaka N, Taguchi J, Kimura Y, et al. Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery. Atherosclerosis. 1999; 142 (1): 41-46.
13. Rogers KC, Oliphant CS, Finks SW,. Clinical efficacy and safety of cilostazol: a critical review of the literature. Drugs. 2015; 75 (4): 377-395.
14. Douglas JS Jr, Holmes DR Jr, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005; 112 (18): 2826-2832.
15. Takigawa T, Matsumaru Y, Hayakawa M, Nemoto S, Matsumura A,. Cilostazol reduces restenosis after carotid artery stenting. J Vasc Surg 2010; 51 (1): 51-56.
16. Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J. 2005; 69 (10): 1256-1259.
17. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151 (4): 264-269, W264.
18. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Julian PT Higgins and Sally Green. Web site. http://handbook.cochrane.org/index.htm#chapter-8/8-10-allocation-sequence-concealment.htm. Chapter 8. Accessed August 31, 2015.
19. Ikushima I, Yonenaga K, Iwakiri H, Nagoshi H, Kumagai H, Yamashita Y,. A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine. Med Devices (Auckl). 2011; 4: 83-89.
20. Iida O, Soga Y, Hirano K, et al. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis. J Endovasc Ther. 2011; 18 (6): 753-761.
21. Soga Y, Iida O, Hirano K, Suzuki K, Yokoi H, Nobuyoshi M,. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol. Catheter Cardiovasc Interv. 2012; 79 (4): 541-548.
22. Suzuki K, Iida O, Soga Y, et al. Long-term results of the S.M.A.R.T. Control(TM) stent for superficial femoral artery lesions, J-SMART registry. Circ J. 2011; 75 (4): 939-944.
23. Kodama A, Sugimoto M, Kuma S, Okazaki J, Mii S, Komori K,. Clinical outcomes after infrainguinal bypass grafting for critical limb ischaemia in patients with dialysis-dependent end-stage renal failure. Eur J Vasc Endovasc Surg. 2014; 48 (6): 695-702.
24. Schulman S, Kearon C,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3 (4): 692-694.
25. Warner CJ, Greaves SW, Larson RJ, et al. Cilostazol is associated with improved outcomes after peripheral endovascular interventions. J Vasc Surg. 2014; 59 (6): 1607-1614.
26. Benjo AM, Garcia DC, Jenkins JS, et al. Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials. Open Heart. 2014; 1 (1): e000154.
27. Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation. 2013; 127 (23): 2307-2315.
28. Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA,. Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. CMAJ. 2000; 163 (11): 1441-1448.
29. Chen J, Meng H, Xu L, et al. Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. J Thromb Thrombolysis. 2015; 39 (1): 23-34.
30. Perez P, Esteban C, Sauquillo JC, et al. Cilostazol and outcome in outpatients with peripheral artery disease. Thromb Res. 2014; 134 (2): 331-335.
31. Hashimoto A, Tanaka M, Takeda S, Ito H, Nagano K,. Cilostazol induces PGI2 production via activation of the downstream Epac-1/Rap1 signaling cascade to increase intracellular calcium by PLCepsilon and to activate p44/42 MAPK in human aortic endothelial cells. PLoS One. 2015; 10 (7): e0132835.
32. Oyama N, Yagita Y, Kawamura M, et al. Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. Stroke. 2011; 42 (9): 2571-2577.
33. Moncada S,. Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci. 2006; 361 (1469): 735-759.
34. Chao TH, Tseng SY, Chen IC, et al. Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. Int J Cardiol. 2014; 172 (2): e371-e374.
35. Rizzo M, Corrado E, Patti AM, Rini GB, Mikhailidis DP,. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? Expert Opin Pharmacother. 2011; 12 (4): 647-655.
36. Bangalore S, Singh A, Toklu B, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014; 1 (1): e000068.
37. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109 (7): 523-530.
38. Hiatt WR, Money SR, Brass EP,. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47 (2): 330-336.
39. Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G,. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014; 10: CD003748.
40. Pratt CM,. Analysis of the cilostazol safety database. Am J Cardiol. 2001; 87 (12A): 28D-33D.
41. Leeper NJ, Bauer-Mehren A, Iyer SV, Lependu P, Olson C, Shah NH,. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes. PLoS One. 2013; 8 (5): e63499.
42. Meng Y, Squires H, Stevens JW, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014; 65 (3): 190-197.
43. Simpson EL, Kearns B, Stevenson MD, Cantrell AJ, Littlewood C, Michaels JA,. Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis. Health Technol Assess. 2014; 18 (10): 1-252.